La FDA ha approvato Talzenna per trattare il cancro alla prostata metastatico che non è resistente alla castrazione.

Published Date: 28 Jun 2023

The U. S. For metastatic HRR-mutated castration-resistant prostate cancer (mCRPC), the Food and Drug Administration has approved Talzenna (talazoparib) in combination with enzalutamide.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

La FDA ha approvato Talzenna per trattare il cancro alla prostata metastatico che non è resistente alla castrazione.

2.

Adult overdose deaths on the rise

3.

Legal, Recreational Marijuana Linked to Higher CUD Prevalence.

4.

In Acute Myeloid Leukemia Diagnosed Recently, FLT3 Inhibitor Is Very Effective.

5.

Clinical trial sees dramatic results using radiation to treat breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot